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CD28-B7 blockade in organ dysfunction secondary to cold ischemia/
reperfusion injury. Ischemic injury to cadaver organs is a major risk factor
for development of chronic organ dysfunction. We have recently shown
that the B7 costimulatory pathway plays a critical role in early organ
dysfunction developing after renal cold ischemia/reperfusion injury. We
extended these observations to investigate the role of this pathway in the
development and progression of chronic organ dysfunction following such
injury. Uninephrectomized rats which underwent cold ischemia/reperfu-
sion injury developed progressive proteinuria as compared to uninephrec-
tomized controls. Animals treated with CTLA4Ig, which blocks B7
costimulation, starting on the day of injury had significantly better
long-term survival and developed significantly less proteinuria than con-
trol animals treated with control 1g. RT-PCR analysis of kidney tissue
showed significant reduction in expression of activation and inflammatory
cytokines, chemoattractants, and growth factors, as compared to controls.
Delaying administration of CTLA4Ig for one week, but not four weeks,
after injury was still effective in ameliorating development of progressive
proteinuria. Interestingly, selective blockade of B7-l by a mutant form of
CTLA4Ig had no effect on early or chronic organ dysfunction. These
findings indicate the long-term functional and molecular consequences of
experimental cold ischemia/reperfusion injury, and suggest that B7-2 is
critical in the development of organ dysfunction following ischemic injury,
even in the absence of alloantigen.
Late failure of cadaver allografts remains the major obstacle for
long-term success of organ transplantation [1—3]. Ischemia/reper-
fusion injury associated with organ retrieval, storage and trans-
plantation adversely affects early graft function and influences the
development of chronic graft dysfunction [4, 5]. It has been
demonstrated in experimental models that initial ischemic insult
may increase the "immunogenicity" of the organ by up-regulating
MHC class II antigens [6]. We have recently demonstrated [7, 8],
in a rat model, that T lymphocytes and macrophages infiltrated
Note: See Editorial by Coffman, p. 1707.
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ischemic tissue within a few days of cold ischemia/reperfusion
injury. This was associated with up-regulation of the T cell
costimulatory molecule B7 [8], and increased expression of acti-
vation and inflammatory cytokines and growth factors [7, 8]. We
also showed that blocking the B7 T cell costimulatoiy activation
pathway with the fusion protein CTLA4Ig reduced early organ
dysfunction following ischemia/reperfusion injury associated with
decreased cellular infiltration and reduced expression of activa-
tion and inflammatory cytokines and growth factors [8]. There are
at least two well recognized members of the B7 family of
molecules, B7-1 (CD8O) and B7-2 (CD86) [9]. Expression of these
molecules have been shown to be differentially regulated [2, 10],
and there are data to indicate that these molecules may have
different functions [11—13]. Freeman et al suggested that B7-1
may be responsible for signaling Thi, while B7-2 may signal Th2
cells [111. In vivo, B7-1 may play the dominant role in signaling
encephalitogenic T cells in the experimental autoimmune enceph-
alomyelitis model [12], while B7-2 may be the dominant costimu-
latory molecule for T cells mediating diabetes in the NOD mouse
model [13]. In this study we extended our initial observations and
investigated the role of B7 costimulatory pathway in development
and progression of chronic organ dysfunction following cold
ischemia/reperfusion injury, and studied selective contribution of
B7-1 in this form of injury.
METHODS
Experimental design and operative technique
Inbred male LEW rats (Harlan Sprague-Dawley, Indianapolis,
IN, USA) of 250 to 300 g underwent cold ischemia!reperfusion of
left kidney with simultaneous right nephrectomy under anesthe-
sia, as previously described [7, 8], Briefly, after removal of the
right kidney, the aorta was occluded proximal and distal to the left
renal artery, and the left renal vein clamped with a vascular clip
near its junction with the inferior vena cava. The aorta was then
catheterized with a silicone tube (Silicone Medical Grade Tubing,
0.02 inch inside diameter, 0.037 inch outside diameter; Baxter
Scientific Products, Boston, MA, USA) and a drainage vent made
in the renal vein distal to the vascular clip. The isolated kidney was
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then perfused slowly (2 to 3 mm) with 10 ml of iced perfusate of
University of Wisconsin (UW) solution with an additional 10% by
volume of 25% albumin (Albutein; Alpha Therapeutic Corpora-
tion, Los Angels, CA, USA) and 10% by volume of 50% Dextrose
(Abbott Laboratories, North Chicago, IL, USA). The vascular
pedicle was then clamped at the level of the hilum for a total
ischemic time of 45 minutes. During that time, the involved
vessels were repaired with 7 to 0 monofilament suture (Proline;
Ethicon Inc., Somerville, NJ, USA) and the other clamps re-
leased.
Treatment protocols
CTLA4Ig, "mutant Y100F" CTLA4Ig and the control human
fusion protein L6 were gifts of Dr. Peter Linsley (Bristol-Myers
Squibb, Seattle, WA, USA). "Mutant Y100F" CTLA4Ig was
made by a substitution in the conserved MYPPPY motif of the
CDR3-like region of CTLA4, the resultant "mutant" CTLA4Ig
selectively binds to B7-1 but not B7-2 [14]. The experimental
group was given CTLA4Ig or mutant CTLA4IgY100F for one
week (0.5 mg i.v. on the day operation and 0.1 mg daily for seven
days), the controls received a similar protocol of control fusion
protein. In separate experiments the fusion proteins were admin-
istered starting at one week or four weeks after the ischemic
insult. Unmodified uninephrectomized rats were used as negative
controls.
Functional measurements
Blood samples (0.5 ml) for creatinine determination were
obtained from the tail vein at 0, 1, 2, 3 and 5 days after
reperfusion. Creatinine was measured by a modified Jaffe's
reaction on an autoanalyzer (Model 911; Hitachi, Indianapolis,
IN, USA). Urine (24 hr) was collected every four weeks from the
time of ischemia/reperfusion injury to 40 weeks to determine
proteinuria, which in prior studies has been shown to be an
accurate and sensitive assessment of chronic renal dysfunction in
the rat [15, 161. Protein excretion was determined by measuring
precipitation after interaction with 3% sulfosalicylic acid. Turbid-
ity was assessed by absorbance at a wavelength of 595 nm using a
Coleman Junior II spectrophotometer [17].
. 3.
0
a)
Week
Fig. 2. Twenty-four-hour urinary protein excretion in uninephrectomized
animals subjected to ischemia/reperfusion injury. (A) Progressive pro-
teinuria following cold ischemic injury occurred in the control Ig treated
animals (0), which was significantly reduced in the CTLA4Ig treated
animals (S), (P < 0.003 at 40 weeks), to similar levels as in uninephrec-
tomized controls (U). (B) Progressive proteinuria following cold ischemic
injury occurred in the CTLA4IgY100F treated animals (A).
Reverse transcriptase polymerase chain reaction
Serial expression of various products was examined hy compet-
itive RT-PCR [7, 8, 16, 18] at 4, 8, 16, 24, 32 and 40 weeks. Total
RNA (2.5 mg) of kidney specimens extracted by the guanidine
isothiocyanate method (Ultraspec RNA kit; Biotex Laboratories,
Inc., Houston, TX, USA) was used for first strand cDNA synthesis
employing 1.2 mg of oligo dT1218 and the Superscript reverse
transcriptase method according to supplier-recommended condi-
tions (GIBCO-BRL, Gaithursberg, MD, USA). The specific prim-
ers B7, IL-2, IFN-y, IL-2R, TNF-a, IL-i, IL-6, IL-12, MCP-1.
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Fig. 1. Survival of uninephrectomized animals subjected to ischemia/
reperfusion injury. Improved survival with CTLA4Ig treatment compared
to control IgG is shown (P < 0.006 at 40 weeks).
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RANTES, iNOS, ICAM-1, endothelin, TGF-3, and f3-actin con-
trol) have been previously published l6, 18, 19].
The competitive PCR for quantification of mRNA was per-
formed as described [16, 18]. For each 25 ml amplification, 2.5ml
of first-strand eDNA product was collected. Two- to sixteenfold
serial dilutions of known quantities of PCR MIMICS were added
to the PCR reaction containing constant amounts of sample target
eDNA. Polymerase chain reaction products (5 ml) were run on
1.5% agarose gel and stained with ethidium bromide, then
gene-specific bands were visualized with ultraviolet light. The
quantities of MIMICS and target eDNA were compared using a
PC SCANJET with analysis by Adobe Photoshop software (Ado-
be mc, Mountain View, CA, USA). Tissues were tested at all time
points for an individual cytokine mRNA transcript as well as for
the control B-actin mRNA transcript. Three animals in each
group were examined for each time period.
Statistical analysis
The results are expressed as arithmetic means ( SEM). Statis-
tical comparisons between groups were performed by Student's
I-test for proteinuria and PCR data, Statistical comparison of
survival data were carried out by the Wilcoxon test.
RESULTS
Prevention of progressive chronic organ dysfunction following
ischemia/reperfusion injury
In our initial study [8] we have demonstrated that B7 blockade
by the fusion protein CTLA4Ig prevented the initial rise in serum
creatinine and development of progressive proteinuria in animals
for up to 24 weeks post-ischemic injury. In this study we extended
these studies and examined the effect of initial cold ischemia/
reperfusion injury on animal survival and development of organ
dysfunction as determined by 24-hour urinary protein excretion
during a follow-up period of 40 weeks. As seen in Figure 1, only
50% of the control animals that underwent ischemia/reperfusion
injury survived to 40 weeks. This was associated with development
of severe progressive proteinuria starting around eight weeks after
injury (Fig. 2). All animals treated with CTLA4Ig survived to 40
weeks when the experiment was terminated (Fig. 2), and devel-
oped significantly less proteinuria (Fig. 2). In fact, the 24-hour
urinary protein excretion in the CTLA4Ig treated animals was not
significantly different from uninephrectomized controls that did
not undergo ischemic injury (Fig. 2A).
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Fig. 3. Progressive increase in gene transcript
levels of T cell associated (A), macrophage
associated (B), and other products and growth
factors (C) following ischemia/reperfusion
injury with control Ig treatment is noted (0).
This is almost completely inhibited by CTLA4Ig
treatment (•)(* < 0.05, **p < 0.001).
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We then examined serial expression patterns of key T cell and
macrophage activation products and growth factors in kidneys of
animals undergoing ischemia/reperfusion injury by semiquantita-
tive competitive RT-PCR. The mRNA expression of activation
and inflammatory cytokines and growth factors were increased
substantially following the ischemia/reperfusion insult in control
animals (Fig. 3). Expression of the T cell cytokines IL-2, IFN-y,
TNF-a, and IL-2R; the macrophage products IL-i, IL-6, IL-12;
the chemoattractants MCP-1 and RANTES; iNOS; ICAM-1 and
endothelin; and the fibrogenic growth factor TGF-13 were all
highly expressed in kidneys of control animals starting early after
injury and progressively increasing through the follow-up period
of 40 weeks (Fig. 3), This paralleled progressive graft dysfunction
as determined by development of progressive proteinuria in these
animals (Fig. 2). Interestingly, animals treated with CTLA4Ig
showed an almost complete absence of up-regulation of all the
products tested (Fig. 3), confirming at the molecular level the
observed differences in organ function above.
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Interruption of progression of chronic organ dysfunction
We then investigated the effect of blocking the CD2S-B7 T cell
costimulatory pathway "late" after the initial ischemic injury on
development of progressive organ dysfunction. These studies are
relevant since they address the question of whether early ischemic
injury leads to a programmed event resulting in chronic organ
dysfunction, and may have therapeutic applications in clinical
practice. In order to address this issue, two further groups of
animals were set up. In the first group administration of CTLA4Ig
was administered in the same protocol as in the original treatment
group but delayed until one week post-injury. Animals with this
delayed treatment still had decreased protein excretion compared
with the control group (Fig. 4A). By contrast, animals treated
continuously from weeks 4 to 8 post-ischemic injury (0.5 mg i.v.
twice weekly) had no effect on 24-hour urinary protein excretion
(Fig. 4B).
Role of selective B7-1 blockade
Since CTLA4Ig binds to both B7-1 and B7-2 costimulatory
molecules, we used a mutant form of CTLA4Ig, CTLA4Ig Y100F,
which selectively binds to and blocks B7-I costimulation in mouse
and rat models [14, 20, 21] to study the role of B7-1 costimulatory
molecule in ischemia/reperfusion injury. Administration of
CTLA4IgY100F (0.5 mg on day of injury followed by 0.1 mg/day
for 1 week) had no effect on either early (Fig. 5) or late chronic
organ dysfunction (Fig. 2B). In addition, administration of
CTLA4IgY100F starting at one week (Fig. 4A) or four weeks
(Fig. 4B) post-injury, in a similar protocol to wild type CTLA4Ig,
also had no effect on development of progressive organ dysfunc-
tion as determined by 24-hour protein excretion.
DISCUSSION
Ischemia/reperfusion associated with kidney retrieval, storage
and transplantation affects early graft function and influences the
development of acute rejection and late graft dysfunction [4, 5].
Detailed knowledge of the cellular and molecular dynamics
occurring in the kidney following ischemia/reperfusion injury is
limited. It has been demonstrated that ischemic injury results in
up-regulation of class II MHC molecules, thus increasing the
"immunogenicity" of the ischemic organ [61. We [7] and others
[221 have recently reported on the expression patterns of key
cellular and molecular markers in an experimental models of cold
ischcmia/reperfusion injury. We also reported that the B7 T cell
costimulatory activation pathway plays a key role in this form of
injury; blocking CD28-B7 T cell costimulation prevented transient
renal dysfunction and in situ mononuclear cell infiltration and
activation [81. In this study we extended these observations to
show that blocking B7 prevented development of progressive
organ dysfunction and mortality, associated with inhibition of
mononuclear cell activation in the ischemic organ. In addition,
CD28-B7 blockade, at one week but not at four weeks, after the
initial injury was still effective in interrupting progression of
chronic organ dysfunction. We also show that selective B7-1
blockade appears to be insufficient to prevent ischemia/reperfu-
sion injury. The early (within hours) up-regulation of expression
of' B7 by RT-PCR reported in our initial study [8] is consistent
with the hypothesis that B7-2 may he the relevant costimulatory
molecule in our model, since B7-2 expression is up-regulated
earlier after immune activation [10, 20]. What is interesting in the
Week
Fig. 4. Effect of late administration of CTLA4Ig on 24-hour urinary
protein excretion. (A) Delayed administration of CTLA4Ig to one week
post-injury still significantly decreased 24-hour urinary protein excretion
in CTLA4Ig treated animals (•) compared with control animals (0), hut
this protocol was not effective when the "mutant" CTLA4IgY I OOF was
used (•). (B) Delay and continuous treatment with either CTLA41g or
CTLA4IgYIOOF from weeks 4 to 8 had no effect on urinary protein
excretion.
current study is that even delayed blockade of B7-1, at a time
when expression of this costimulatory molecule should be signif-
icantly up-regulated [10, 20], is still ineffective in ameliorating
ischemic injury. These data indicate the importance of B7-2
costimulatory molecule in our model, although reagents which
specifically block rat B7-2 are currently not available to formally
prove this hypothesis.
The pathogenetic mechanisms responsible for chronic organ
dysfunction developing after initial ischemia/reperfusion injury
remain unknown. The serial RT-PCR data indicate that ischemic
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interaction of ICAM-1:LFA-1 and LFA-3:CD2. This CD28-B7
induced adhesion required specific T cell signaling via protein
kinase C. Taken together with results of these two studies, our
data suggest that blocking B7 costimulatory molecules may result
in inhibition of adhesion of neutrophils and mononuclear cells to
renal endothelium, resulting in decreased infiltration into the
organ and prevention of the subsequent injury. We realize that
our data with blockade of the B7 costimulatory pathway by
CTLA4Ig do not provide definitive proof as to a direct pathoge-
netic role of T cells in cold ischemia/reperfusion injury, since it is
possible that blockade of B7-2 may have a direct effect on
monocytes/macrophages or endothelial cells. Dissecting these
mechanisms is important for future development of strategies to
prevent injuly in cadaver organ transplantation and possibly other0 1 2 3 4 5 ischemic disorders.
Fig. 5. Plasma creatinine levels in animals subjected to ischemia/reper-
fusion injury. The transient rise in creatinine in control Ig treated animals
(0) was also present in the "mutant" CTLA4IgY1 OOF treated group (A),
but not in the CTLA4Ig treated animals (•), which had similar levels of
creatinine as the control uninephrectomized controls (LI) [8].
organs express key T cell and monocyte/macrophage activation
and inflammatory cytokines, chemoattractants and growth factors.
The exact contribution of each product to the process of chronic
organ dysfunction needs further evaluation, however. IFN-y and
TNF-a are potent inducers of MHC class II antigen [22] and B7
[101 expression; both contribute to increased "immunogenecity"
of the ischemic organ. In the absence of an immune response to
alloantigen, it is interesting to hypothesize that the ischemic injury
may result in "exposure" of neoantigens that can be recognized by
T cells on infiltrating antigen-presenting cells expressing class II
MHC and capable of providing a costimulatory signal. Oxygen
free radicals are known to provide a signal for T cell activation.
Therefore, an alternative hypothesis is that T cells get activated by
oxygen free radicals released during cold ischemia/reperfusion
injury. CTLA4Ig, by blocking the second or costimulatory signal
of T cell activation, inhibits full T cell activation and prevents
injury to the organ [231. The fact that B7 blockade at one week,
but not four weeks, post-injury was effective in interrupting
progression of organ dysfunction suggest that the T cell-mono-
cyte/macrophage activation cascade is critical in the early time
period in initiating post-ischcmic injury. This is consistent with
data from Perico et al [24] in an acute renal allograft rejection
model, which indicated that delaying CD28-B7 blockade until
time of cellular rejection is ineffective in preventing further organ
dysfunction.
Other products that may contribute to progressive organ dys-
function include IL-6, iNOS, and endothelin, which may be
relevant to the development of progressive proteinuria [25], and
TGF-13, which may be important in causing interstitial fibrosis
[26]. What is clear, however, is that blocking proximal events in T
cell and macrophage activation by blocking the B7 costimulatory
pathway markedly inhibits in situ up-regulation of cytokine,
chemokine and growth factor expression, and prevents develop-
ment of progressive organ dysfunction. Previous studies by Kelly
et al showed that blocking ICAM-1 protects the kidney from
ischemic injury [27]. Turcovski-Corrales et al [28] indicated that
CD28-B7 interactions promote T cell adhesion mediated by the
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